TP53 and Dravet syndrome: The findings revealed that NDMM patients in DS stage III, without ASCT, in conjunction with +1q21, IgH cytogenetic abnormality, P53 deletion, or RB/D13S319 deletion, exhibited significantly poorer PFS outcomes (p < 0.05) as depicted in Table 3.